Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis

Nicole Trepanowski; Rebecca M Yim; Rachel Wetstone; Elizabeth MacDonald; Sarah Servattalab; Subin Jacob-George; John E Harris

doi:10.1016/j.jdcr.2023.09.033

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis

JAAD Case Rep. 2023 Oct 11:42:26-30. doi: 10.1016/j.jdcr.2023.09.033. eCollection 2023 Dec.

Authors

Nicole Trepanowski^{1

2}, Rebecca M Yim^{2

3}, Rachel Wetstone^{2

4}, Elizabeth MacDonald², Sarah Servattalab², Subin Jacob-George², John E Harris²

Affiliations

¹ Boston University School of Medicine, Boston, Massachusetts.
² Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
³ Tulane University School of Medicine, Tulane, Louisiana.
⁴ Florida International University College of Medicine, Herbert Wertheim College of Medicine, Miami, Florida.

No abstract available

Keywords: BMP6; Dynein light chain Tctex-type 3; Dynlt3; LRP5; LRP6; Monoclonal; Pathway; RANKL; Romosozumab; Signaling; Wnt; activity; adverse effect; antibody; bone morphogenetic protein 6; flare; injection; low-density lipoprotein receptor-related protein 5; low-density lipoprotein receptor-related protein 6; medication; osteoporosis; progression; receptor activator of nuclear factor κB ligand; sclerostin; vitiligo; ß-catenin.

Publication types

Case Reports